Axiomer® platform applicability and potential in therapeutically relevant models for targeted RNA editing presented at TIDES EU 2018 by Antti Aalto - ProQR Therapeutics
… Massachusetts, USA. At ProQR, we are on a mission to edit RNA, treat disease and change lives. A team of 180+ … of the communities we serve. Our proprietary Axiomer™ RNAediting technology platform enables the editing of …
… Massachusetts, USA. At ProQR, we are on a mission to edit RNA, treat disease and change lives. A team of 180+ … of the communities we serve. Our proprietary Axiomer™ RNAediting technology platform enables the editing of …
Chardan’s 9th Annual Genetic Medicines Conference – October 21, 2025
Company management will participate in an RNA Editing panel at 1:00 p.m. ET and will conduct 1x1 investor meetings in conjunction with the conference.
ProQR has announced the completion of an in-depth strategic review designed to deliver on our commitment to advance RNA therapies for diseases with high unmet need. We are also sharing additional analyses of the sepofarsen Illuminate trial.
